ATE557030T1 - Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung - Google Patents

Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung

Info

Publication number
ATE557030T1
ATE557030T1 AT04722965T AT04722965T ATE557030T1 AT E557030 T1 ATE557030 T1 AT E557030T1 AT 04722965 T AT04722965 T AT 04722965T AT 04722965 T AT04722965 T AT 04722965T AT E557030 T1 ATE557030 T1 AT E557030T1
Authority
AT
Austria
Prior art keywords
halogen
medical
composition containing
condensed heterocyclic
containing same
Prior art date
Application number
AT04722965T
Other languages
English (en)
Inventor
Nobuhiko Fushimi
Shigeru Yonekubo
Hideyuki Muranaka
Hiroaki Shiohara
Hirotaka Teranishi
Kazuo Shimizu
Fumiaki Ito
Masayuki Isaji
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Application granted granted Critical
Publication of ATE557030T1 publication Critical patent/ATE557030T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
AT04722965T 2003-03-31 2004-03-24 Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung ATE557030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003097152A JP2004300102A (ja) 2003-03-31 2003-03-31 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
PCT/JP2004/004009 WO2004087727A1 (ja) 2003-03-31 2004-03-24 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途

Publications (1)

Publication Number Publication Date
ATE557030T1 true ATE557030T1 (de) 2012-05-15

Family

ID=33127540

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04722965T ATE557030T1 (de) 2003-03-31 2004-03-24 Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung

Country Status (10)

Country Link
US (1) US7566699B2 (de)
EP (1) EP1609798B1 (de)
JP (2) JP2004300102A (de)
KR (1) KR101170715B1 (de)
CN (1) CN100418977C (de)
AT (1) ATE557030T1 (de)
CA (1) CA2520436C (de)
ES (1) ES2383892T3 (de)
TW (1) TWI377210B (de)
WO (1) WO2004087727A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200524951A (en) 2003-08-01 2005-08-01 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
TW200521131A (en) 2003-08-01 2005-07-01 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
PT2896397T (pt) 2003-08-01 2017-11-23 Mitsubishi Tanabe Pharma Corp Novos compostos que possuem actividade inibidora dirigida contra transportadores de glucose dependentes do sódio
CA2549025A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
AU2004261264A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-O-glucosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
EP1724277A4 (de) * 2004-03-04 2012-05-02 Kissei Pharmaceutical Derivat mit kondensiertem heterocyclus, medizinische zusammensetzung, die dieses enthält, und deren medizinische verwendung
JP4902348B2 (ja) 2004-03-04 2012-03-21 キッセイ薬品工業株式会社 含窒素縮合環誘導体、それを含有する医薬組成物およびその医薬用途
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP5110697B2 (ja) * 2005-06-27 2012-12-26 第一三共株式会社 固形製剤
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2019679B1 (de) 2006-05-23 2018-06-20 Theracos, Inc. Glucosetransporthemmer und anwendungsverfahren
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
RU2492175C2 (ru) 2007-04-02 2013-09-10 Теракос, Инк. Бензиловые производные гликозидов и способы их применения
EP3318562A3 (de) * 2007-08-23 2018-09-12 Theracos Sub, LLC Benzylbenzenderivate und verfahren zur verwendung
BRPI0816258B8 (pt) 2007-09-10 2022-12-27 Mitsubishi Tanabe Pharma Corp processo para a preparação de compostos úteis como inibidores de sglt
GB0718023D0 (en) * 2007-09-14 2007-10-24 Univ London Pharmacy Anti-bacterial agents
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
DK2324002T3 (en) * 2008-08-22 2016-12-19 Theracos Sub Llc Methods of making of sglt2 inhibitors
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010082661A1 (ja) * 2009-01-19 2010-07-22 国立大学法人富山大学 1,5-ａｇ含有組成物
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ES2416459T3 (es) 2009-07-10 2013-08-01 Janssen Pharmaceutica, N.V. Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
SI2488515T1 (sl) 2009-10-14 2017-04-26 Janssen Pharmaceutica Nv Postopek za pripravo spojin, ki so uporabne kot inhibitorji SGLT2
KR101426180B1 (ko) 2009-11-02 2014-07-31 화이자 인코포레이티드 디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
SG10201506114UA (en) 2010-05-11 2015-09-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2697218B1 (de) 2011-04-13 2016-05-25 Janssen Pharmaceutica NV Verfahren zur herstellung von verbindungen die als sglt2 inhibitoren verwendbar sind
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
US9562029B2 (en) 2011-06-25 2017-02-07 Xuanzhu Pharma Co., Ltd. C-glycoside derivatives
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
EP2968375B1 (de) 2013-03-14 2019-06-12 MSD International GmbH Verfahren zur herstellung von sglt2-inhibitoren
WO2015032272A1 (zh) * 2013-09-09 2015-03-12 江苏豪森药业股份有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
GB201421010D0 (en) * 2014-11-26 2015-01-07 N Gene Res Lab Inc Method
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6447557B2 (ja) * 2016-03-24 2019-01-09 日亜化学工業株式会社 発光装置の製造方法
CN110590722B (zh) * 2019-10-22 2022-11-04 温州大学 2-三氟甲基苯并呋喃衍生物的合成方法
CN110804079B (zh) * 2019-11-05 2021-02-12 广东省农业科学院蚕业与农产品加工研究所 一种具有dppiv酶抑制活性的呋喃香豆素及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6600015B2 (en) * 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
EP1369422B1 (de) * 2001-02-14 2008-07-23 Japan Science and Technology Agency Verfahren zur herstellung von alkenylphosphinoxiden oder alkenylphosphinsäureestern
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
EP1381361B1 (de) * 2001-04-04 2009-02-25 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
CA2672001A1 (en) * 2001-04-27 2002-11-07 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
CA2448741C (en) * 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
WO2003011880A1 (fr) * 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
CA2549025A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides

Also Published As

Publication number Publication date
EP1609798A4 (de) 2009-06-17
TW200510442A (en) 2005-03-16
JP2004300102A (ja) 2004-10-28
ES2383892T3 (es) 2012-06-27
CN100418977C (zh) 2008-09-17
JPWO2004087727A1 (ja) 2006-06-29
JP4753716B2 (ja) 2011-08-24
EP1609798B1 (de) 2012-05-09
EP1609798A1 (de) 2005-12-28
CA2520436A1 (en) 2004-10-14
WO2004087727A1 (ja) 2004-10-14
CA2520436C (en) 2012-01-24
CN1784415A (zh) 2006-06-07
TWI377210B (en) 2012-11-21
US7566699B2 (en) 2009-07-28
KR101170715B1 (ko) 2012-08-03
US20060247179A1 (en) 2006-11-02
KR20050119179A (ko) 2005-12-20
EP1609798A9 (de) 2012-01-11

Similar Documents

Publication Publication Date Title
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
ATE469161T1 (de) Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
NO20064412L (no) Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav
DE60009929D1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
ATE315555T1 (de) Thiazolderivate und ihre verwendung als cdk- inhibitoren
CA2474578A1 (en) Novel pyridin- and pyrimidin-derivatives
TWI255817B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
SE0102299D0 (sv) Compounds
SE0102300D0 (sv) Compounds
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
WO2003011880A1 (fr) Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
TNSN05320A1 (en) Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors
SE0102764D0 (sv) Compounds
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20072389L (no) Substituerte benzokinolizinderivater
EP1637539A4 (de) Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung
BR0318533A (pt) azolidinacarbonitrilas e seu uso como inibidores de dpp-iv
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
HK1077070A1 (en) Oligosaccharide derivative
TW200505892A (en) Substituted 3-(benzoylureido)thiophene derivatives, processes for preparing them and their use
NO20042881L (no) Substituerte cykloheksan-derivater